DanCann Pharma A/S
31 Oct - 11 Nov 2022Rights issue
DanCann Pharma is a Danish biopharmaceutical company powered by cannabinoids, licensed for production and distribution of products based on cannabinoids.
Cannabinoids is the active components from the plant cannabis. The Company conducts its business through work with both cannabis and cannabinoids as handling of the cannabis plant is part of the process in producing cannabinoids, the component used for therapeutic and medical purposes. DanCann Pharma is an early-stage company with the intention to establish itself on the European medicinal cannabis market. The Company is overall focused on discovering, developing, manufacturing, and commercializing novel cannabinoid therapeutics in a broad range of disease areas, dedicated to the commercialization of innovative prescription products targeting the European market. The Company already has market activities in Denmark, and has also set its focus on Germany in particular.
Read more on the company's website
The offer in summary
Record date: 27 October 2022
Subscription period: 31 October - 11 November 2022
Subscription rights: Those who on the Record Date 27 October 2022 were registered as shareholders have preferential rights to subscribe for units in the Rights Issue. For one (1) existing share held on the Record Date the holder receives one (1) unit right. Six (6) unit rights entitle the subscription for one (1) new unit. One (1) unit consits of ten (10) new shares and six (6) warrants of series TO 2.
Subscription price: DKK 6.00
Emission volume: Maximum of 4,744,714 units which corresponds to about MDKK 28.5
Trading with unit rights: 31 October - 9 November 2022
Marketplace: Spotlight Stock Market
Financial advisor: Corpura Fondkommission
